Close

Veeva Digital Clinical Trials Survey Report

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

CDMO Market For Small Molecule Innovation Soars By 2033

It has been anticipated that the market for contract...

API Sourcing Redefining Global Pharmaceutical Supply Chain

The COVID-19 pandemic went on to expose crucial susceptibility...

Pharmaceutical Fine Chemicals Market to hit $235bn by 2030

The pharmaceutical fine chemicals market is all set for...

The Overall Spectrum Study of the Global HPAPI Market

High-potency active pharmaceutical ingredients - HPAPIs happen to represent...

Veeva released the largest survey on digital trials examining the opportunities and implications of decentralized approaches on clinical trials by gathering the experiences and opinions of more than 280 clinical leaders worldwide. In case you find it useful for any stories you or your team are writing in the future, I’ve shared below some key takeaways.

Rapid shift to decentralized trials: Rapid adoption of decentralized technologies accelerated to enable remote execution during COVID-19. Today, most (87%) use some type of decentralized technology, up 59 percentage points from pre-pandemic (28%).

More clinical apps: Companies added an average of four new applications to their clinical landscape, leading to issues with data collection and stakeholder collaboration and impacting study quality and speed.

Fragmented technology is causing challenges: Nearly all sponsors and CROs (99%) report significant challenges with decentralized trials. Major changes are happening to address lack of site technology adoption (70%) and increased burden for technology-averse patients (50%).

Future transition to completely Digital Trials: Most respondents (95%) say they have initiatives underway to establish a digital foundation for patient and site-centric trials that will better support sites, improve data sharing and collaboration, and eliminate silos through a connected network. Respondents are accelerating digital transformation to advance toward paperless trials.

You can read the full report here.

Latest stories

Related stories

CDMO Market For Small Molecule Innovation Soars By 2033

It has been anticipated that the market for contract...

API Sourcing Redefining Global Pharmaceutical Supply Chain

The COVID-19 pandemic went on to expose crucial susceptibility...

Pharmaceutical Fine Chemicals Market to hit $235bn by 2030

The pharmaceutical fine chemicals market is all set for...

The Overall Spectrum Study of the Global HPAPI Market

High-potency active pharmaceutical ingredients - HPAPIs happen to represent...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back